Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments), Technology (IVD Testing, Anatomic pathology, Imaging, Biopsy), Type (Tumors, Breast, Lung Cancer), Application, End User (Hospitals) & Region – Global Forecast to 2031

Market Size
$29.86B
MARKET SIZE, 2026
Projected Market Size
$44.92B
MARKET SIZE, 2031
CAGR
7.0%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

CANCER DIAGNOSTICS MARKET SIZE, SHARE & GROWTH SNAPSHOT

cancer-diagnostics-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global cancer diagnostics market is projected to grow from USD 29.86 billion in 2026 to USD 44.92 billion by 2031, at a CAGR of 7.0% during the forecast period. The market was valued at USD 27.62 billion in 2025. The rising global burden of cancer, coupled with increasing awareness of the importance of early detection and timely diagnosis, is a major factor driving demand for cancer diagnostics. Growing incidences of breast, lung, colorectal, prostate, and other cancers are accelerating the adoption of advanced diagnostic technologies such as molecular diagnostics, liquid biopsy, next-generation sequencing (NGS), immunohistochemistry (IHC), and companion diagnostics. The expanding aging population, increasing healthcare expenditure, and government-led cancer screening initiatives are further supporting market growth. In addition, continuous advancements in precision oncology, biomarker-based testing, digital pathology, and AI-enabled diagnostic solutions are improving diagnostic accuracy, reducing turnaround times, and enabling personalized treatment decisions. As healthcare providers increasingly emphasize early cancer detection and targeted therapies, demand for cancer diagnostic solutions across hospitals, clinical laboratories, and specialized cancer centers is expected to remain strong throughout the forecast period.

KEY TAKEAWAYS

  • SEGMENT LEADERSHIP:
    Regional Leader: Asia Pacific is expected to register the highest CAGR of 6.5% during the forecast period.
    Product Leader: IVD testing products segment is estimated to lead the cancer diagnostics market during the forecast period, driven by the increasing demand for continuous monitoring solutions.
    End User Leader: Clinical laboratories segment is estimated to lead the cancer diagnostics market during the forecast period, driven by rising patient admissions and increasing demand for continuous monitoring.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), QIAGEN N.V. (Netherlands), and Hologic, Inc. (US) were identified as Star Players in the cancer diagnostics market due to their strong focus on innovation, extensive product portfolios, broad industry presence, and robust operational and financial capabilities.
    Myriad Genetics, Inc. (US), Natera, Inc. (US), and NeoGenomics Laboratories, Inc. (US) are among the few key startups and SMEs due to their strong product portfolio and business strategies.

Rapid improvements in healthcare infrastructure across emerging economies are significantly contributing to the growth of the cancer diagnostics market. Governments and private healthcare providers are increasing investments in cancer hospitals, diagnostic laboratories, pathology centers, and advanced imaging facilities to strengthen access to early and accurate cancer detection services. These initiatives are improving diagnostic capabilities and encouraging the adoption of advanced technologies such as molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, digital pathology, and companion diagnostics. Additionally, increasing healthcare expenditure, expanding health insurance coverage, and national cancer screening programs are supporting broader access to cancer diagnostic services across urban and rural settings. The growing emphasis on precision medicine, early disease detection, and personalized oncology care is driving the integration of advanced cancer diagnostics into routine clinical practice. As a result, underserved regions are witnessing increasing demand for affordable, reliable, and technologically advanced cancer diagnostic solutions, creating opportunities for manufacturers to develop innovative, accessible, and high-performance diagnostic platforms tailored to evolving healthcare needs.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The cancer diagnostics market is evolving from conventional laboratory-based and pathology-centric testing toward rapid, precision-driven, and patient-centric diagnostic solutions that enable earlier detection and more informed clinical decision-making across hospitals, diagnostic laboratories, specialty cancer centers, and decentralized care settings. Rising global cancer incidence, increasing emphasis on early diagnosis, and growing demand for minimally invasive testing are driving the adoption of advanced diagnostic technologies. Innovations in molecular diagnostics, liquid biopsy, next-generation sequencing (NGS), AI-enabled image analysis, digital pathology, and biomarker-based testing are transforming cancer diagnostics by improving accuracy, enabling personalized treatment selection, and delivering faster clinical insights. As healthcare providers increasingly prioritize precision oncology, companion diagnostics, and integrated cancer care, manufacturers are focusing on multiplex testing platforms, automation, strategic collaborations, and connected digital ecosystems. The expanding adoption of screening programs, home-based sample collection, remote diagnostics, and cloud-enabled data management is further accelerating innovation and broadening access to advanced cancer diagnostic solutions worldwide.

cancer-diagnostics-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Growing pet ownership and pet humanization
  • Increasing incidence of chronic diseases and age-related conditions
RESTRAINTS
Impact
Level
  • High capital cost of advanced monitoring systems limiting adoption among small veterinary practices
OPPORTUNITIES
Impact
Level
  • Expanding veterinary infrastructure and rising animal healthcare expenditure in emerging economies
  • Technological advancements in veterinary monitoring equipment creating growth opportunities
CHALLENGES
Impact
Level
  • Veterinary workforce shortage and limited technical expertise in emerging economies

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing pet ownership and pet humanization

Pet ownership has climbed steadily across major markets, and a growing share of owners now treat dogs and cats as family members rather than property. That shift is reflected directly in veterinary spending: owners are more willing to pay for advanced diagnostics, surgery, and the monitoring equipment that keeps a pet safe during and after a procedure. A rising incidence of chronic and age-related conditions, including cardiac and renal disease in older pets, adds a second layer of demand, since these conditions require monitoring at every visit rather than a single check. Growing veterinary surgical volumes reinforce both trends, since every anesthetized case requires continuous ECG, blood pressure, and oxygenation monitoring. Together, these factors keep underlying demand for monitoring hardware on a steady upward path.

Restraint: High capital cost of advanced monitoring systems limiting adoption among small veterinary practices

Advanced multiparameter monitors, telemetry systems, and central monitoring stations carry a high upfront cost, which is harder to justify for a one- or two-doctor practice than for a corporate hospital chain. Smaller clinics often continue to rely on older analog equipment or basic single-parameter devices. Financing and leasing programs help, but budget sensitivity still slows replacement cycles across the independent practice segment, which represents a large share of the installed base.

Opportunity: Expanding veterinary infrastructure and rising animal healthcare expenditure in emerging economies

Emerging markets in Asia Pacific, Latin America, and parts of the Middle East are building veterinary hospital capacity and specialty referral networks largely from scratch, giving monitoring equipment makers a chance to establish their platforms before competitors. Rising household incomes and growing pet insurance penetration in these regions are driving animal healthcare spending higher year over year. Moreover, a related opportunity stems from technological advances: wireless, wearable, and AI-assisted monitoring formats let vendors sell into new settings, such as recovery cages and mobile practices, that older wired equipment could not reach. Vendors that pair affordable hardware with local training and distribution partnerships are best positioned to capture both openings.

Challenge: Veterinary workforce shortage and limited technical expertise in emerging economies

Many emerging markets lack a trained veterinary workforce because complex multiparameter systems require trained staff to set up, interpret, and maintain them properly. Vendors face a related challenge in building out local service and support networks quickly enough to keep pace with hospital construction. Equipment makers that invest in simplified interfaces, remote technical support, and in-market training programs have a better chance of converting new infrastructure into actual equipment sales rather than losing deals to workforce constraints.

CANCER DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Develops molecular and tissue-based cancer diagnostic solutions, including companion diagnostics, PCR-based assays, next-generation sequencing (NGS), immunohistochemistry (IHC), and digital pathology for oncology applications. Enables early and accurate cancer detection, supports personalized treatment selection, improves diagnostic confidence, and enhances patient outcomes through precision medicine.
company logo
Develops advanced cancer diagnostic solutions, including molecular diagnostics, HPV testing, cervical cytology, breast imaging (3D mammography/tomosynthesis), biopsy systems, and digital pathology technologies for early cancer detection, diagnosis, and treatment guidance. Enables early and accurate cancer detection, improves screening and diagnostic accuracy, supports personalized treatment decisions, enhances workflow efficiency, and improves patient outcomes through comprehensive oncology diagnostics.
company logo
Provides molecular oncology testing, digital pathology, tissue diagnostics, flow cytometry, and NGS solutions for detecting cancer biomarkers, monitoring disease progression, and guiding targeted therapies. Delivers rapid and precise cancer diagnosis, improves laboratory efficiency, supports personalized oncology care, and enables informed treatment decisions.
company logo
Provides advanced imaging technologies, laboratory diagnostics, molecular testing, and AI-enabled solutions for cancer screening, diagnosis, staging, and therapy monitoring. Enhances early cancer detection, improves diagnostic precision, supports treatment planning, and streamlines oncology workflows.
company logo
Develops molecular diagnostic kits, sample preparation technologies, companion diagnostics, and NGS workflows for identifying cancer-related genetic mutations and biomarkers. Enables accurate biomarker detection, supports precision oncology, accelerates molecular testing, and improves patient stratification for targeted therapies.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The ecosystem of the cancer diagnostics market comprises diagnostic device manufacturers, reagent and assay suppliers, next-generation sequencing (NGS) and molecular diagnostics providers, digital pathology and imaging companies, contract development and manufacturing organizations (CDMOs), distributors, research institutions, regulatory bodies, and healthcare providers. The market includes diagnostic solutions such as molecular diagnostics, companion diagnostics, immunohistochemistry (IHC), in situ hybridization (ISH), liquid biopsy, next-generation sequencing (NGS), PCR-based assays, cytology, digital pathology, and AI-enabled imaging platforms for cancer screening, diagnosis, prognosis, and treatment monitoring. These solutions are supported by laboratory automation, bioinformatics platforms, digital health technologies, and data management software. Manufacturers focus on biomarker discovery, assay development, regulatory approvals, and commercialization, while distributors ensure product availability across hospitals, oncology centers, diagnostic laboratories, and reference laboratories. The ecosystem is further strengthened by advancements in precision oncology, AI-driven diagnostic technologies, reimbursement support, and collaborations among pharmaceutical companies, government agencies, academic research institutions, and public health organizations, driving early cancer detection, personalized treatment, and improved patient outcomes.

cancer-diagnostics-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

cancer-diagnostics-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Cancer Diagnostics Market, by Product

The consumables segment accounts for a significant share of the market due to the recurring demand for reagents, assay kits, antibodies, probes, stains, sequencing consumables, and other laboratory supplies used in cancer screening, diagnosis, biomarker testing, and disease monitoring. The instruments segment includes molecular diagnostic systems, next-generation sequencing (NGS) platforms, PCR instruments, immunohistochemistry (IHC) and in situ hybridization (ISH) systems, digital pathology scanners, flow cytometers, and imaging systems that support accurate cancer detection and characterization. The software & services segment comprises bioinformatics software, image analysis platforms, laboratory information management systems (LIMS), cloud-based data management solutions, installation, maintenance, training, and technical support services that improve workflow efficiency and enable precision oncology. The increasing adoption of precision medicine, growing demand for companion diagnostics and biomarker testing, rising cancer incidence, and continuous advancements in molecular diagnostics, digital pathology, and AI-enabled diagnostic technologies are driving the growth of the cancer diagnostics market.

Cancer Diagnostics Market, by End User

The cancer diagnostics market, by end user, is segmented into hospitals, diagnostic laboratories, oncology clinics and cancer centers, academic & research institutes, and other end users. The hospitals segment holds a significant market share due to the high volume of cancer screening, diagnosis, and treatment procedures, supported by advanced imaging and pathology infrastructure. Diagnostic laboratories remain key end users for molecular diagnostics, biomarker testing, and histopathology services, while oncology clinics and specialized cancer centers are increasingly adopting advanced diagnostic technologies to enable personalized treatment planning and improve patient outcomes. Academic & research institutes are witnessing steady growth, driven by increasing cancer research activities, biomarker discovery, and clinical trials. Other end users include community healthcare centers, physician offices, and ambulatory surgical centers, contributing to the expanding adoption of cancer diagnostic solutions.

REGION

Healthcare Infrastructure Expansion Driving Growth in the Asia Pacific Cancer diagnostics Market

Cancer diagnostics across Asia Pacific is rapidly evolving, driven by increasing cancer incidence, rising healthcare expenditure, and growing government initiatives to strengthen early cancer detection and precision medicine. Countries such as China, India, Japan, South Korea, and Australia are investing significantly in expanding oncology care infrastructure, enhancing laboratory capabilities, and improving access to advanced diagnostic technologies. The establishment of comprehensive cancer centers, molecular diagnostic laboratories, and pathology networks is accelerating the adoption of cancer diagnostic solutions, including next-generation sequencing (NGS), liquid biopsy, immunohistochemistry (IHC), polymerase chain reaction (PCR)-based assays, and companion diagnostics. Additionally, public and private healthcare providers are increasing investments in digital pathology, artificial intelligence (AI)-enabled imaging, and genomic testing platforms to improve diagnostic accuracy, enable personalized treatment selection, and support better patient outcomes. The expansion of cancer screening programs and diagnostic services into tier-2 and tier-3 cities is further driving demand for affordable and accessible cancer testing solutions in previously underserved regions. With continued healthcare infrastructure development, increasing awareness of early cancer detection, and expanding reimbursement for oncology diagnostics, the procurement of cancer diagnostic products—including tissue biopsy instruments, molecular diagnostic systems, liquid biopsy assays, pathology imaging platforms, and biomarker testing kits—is increasing, making healthcare infrastructure expansion a key driver of growth for the Asia Pacific cancer diagnostics market.

cancer-diagnostics-market Region

CANCER DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX

In the cancer diagnostics market, Roche (Star Player) leads with its broad portfolio of molecular and tissue diagnostics, while Natera (Emerging Leader) is rapidly expanding through innovative liquid biopsy and minimal residual disease (MRD) testing solutions.

cancer-diagnostics-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 27.62 Billion
Market Forecast in 2026 (Value) USD 29.86 Billion
Market Forecast in 2031 (Value) USD 44.92 Billion
Growth Rate CAGR of 7.0% from 2026-2031
Years Considered 2024-2031
Base Year 2025
Forecast Period 2026-2031
Units Considered Value (USD Million/Billion), Volume (Thousnad Tests)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Product:
    • IVD Testing
    • Anatomic Pathology
    • Imaging
  • By Technology:
    • PCR
    • In Situ Hybridization (ISH)
    • Immunohistochemistry (IHC)
    • Next-Generation Sequencing (NGS)
    • Microarray
    • Flow Cytometry
    • Immunoassay
    • Positron Emission Tomography (PET)
    • Computed Tomography (CT)
    • Mammography
    • Ultrasound
    • Magnetic Resonance Imaging (MRI)
    • Anatomic Pathology
    • Biopsy
  • By Cancer Type:
    • Lung cancer
    • Breast cancer
    • Colorectal cancer
    • Gastric cancer
    • Head & neck cancer
    • Prostate cancer
    • Cervical cancer
    • Melanoma
    • Myeloma
    • Leukemia
    • Lymphoma
  • By Application:
    • Screening and early detection
    • Diagnosis and disease characterization
    • Treatment decision support
    • Treatment monitoring and disease progression assessment
    • Post-treatment surveillance and recurrence detection
  • By End User:
    • Hospitals
    • Diagnostics Centers
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: CANCER DIAGNOSTICS MARKET REPORT CONTENT GUIDE

cancer-diagnostics-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis Comparative analysis of cancer diagnostic technologies by product type, including tissue biopsy, liquid biopsy, molecular diagnostics (PCR, NGS), immunohistochemistry (IHC), in situ hybridization (ISH), flow cytometry, tumor biomarker assays, companion diagnostics, cytogenetics, digital pathology, and AI-enabled diagnostic platforms, along with evaluation across hospitals, cancer centers, pathology laboratories, reference laboratories, and academic research institutes. Assessment of diagnostic performance through parameters such as sensitivity, specificity, turnaround time, multiplexing capability, biomarker coverage, automation, workflow efficiency, AI integration, regulatory approvals, cost-effectiveness, and suitability for early detection, treatment selection, and disease monitoring to support optimal product selection and improved oncology outcomes.
Company Information Detailed profiles of leading global and regional cancer diagnostics manufacturers including Roche, Thermo Fisher Scientific, Illumina, Agilent Technologies, Danaher (Leica Biosystems, Cepheid, Beckman Coulter), QIAGEN, Abbott, Bio-Rad Laboratories, Guardant Health, Natera, Exact Sciences, Hologic, Sysmex, and BioMérieux, covering product portfolios, diagnostic technologies, strategic initiatives, partnerships, acquisitions, regulatory approvals, clinical developments, and recent product launches. Competitive benchmarking across key players highlighting positioning by technology leadership, oncology test portfolio, companion diagnostics capabilities, liquid biopsy and NGS expertise, digital pathology integration, geographic reach, manufacturing capacity, strategic collaborations with pharmaceutical companies, pricing strategies, and focus across solid tumors, hematologic malignancies, precision oncology, and minimal residual disease (MRD) testing.
Geographic Analysis In-depth regional assessment of the global cancer diagnostics market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with analysis of cancer incidence and prevalence, healthcare infrastructure, laboratory capacity, screening programs, reimbursement landscape, regulatory environment, precision medicine adoption, and access to advanced diagnostic technologies. Country-level market sizing, CAGR forecasts, epidemiological analysis, oncology healthcare expenditure trends, regulatory landscape assessment, reimbursement policies, diagnostic testing penetration, precision oncology adoption, and demand outlook across major markets including the US, Germany, UK, France, China, Japan, India, South Korea, Brazil, and GCC countries.

RECENT DEVELOPMENTS

  • January 2025 : Thermo Fisher Scientific expanded its precision oncology capabilities through a collaboration with the UK Biobank Pharma Proteomics Project, deploying its Olink proteomics platform to analyze approximately 600,000 patient samples for biomarker discovery and future cancer diagnostic development. (Wikipedia)
  • February 2025 : Danaher continued expanding its oncology diagnostics portfolio by strengthening investments across Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics, with a focus on digital pathology, companion diagnostics, and molecular cancer testing to support precision medicine. (Intellectual Market Insights Research)
  • April 2025 : Siemens Healthineers expanded its oncology offering by increasing commercialization of its Varian cancer care ecosystem, integrating AI-enabled imaging, molecular imaging, and digital workflow solutions to improve cancer diagnosis and treatment planning. (Wikipedia)
  • May 2025 : Roche Diagnostics continued expanding its oncology diagnostics leadership by broadening its companion diagnostics and tissue pathology portfolio, supporting precision oncology through additional biomarker-based testing solutions and digital pathology adoption. (Intellectual Market Insights Research)
  • June 2025 : Abbott Laboratories continued expanding its cancer diagnostics capabilities by strengthening its molecular and immunoassay testing portfolio and increasing investment in precision oncology and biomarker-based diagnostics to support decentralized laboratory testing. (Intellectual Market Insights Research)

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
15
2
EXECUTIVE SUMMARY
 
 
 
 
3
PREMIUM INSIGHTS
 
 
 
 
4
MARKET OVERVIEW
This section summarizes market dynamics, key shifts, and high-impact trends shaping demand outlook.
 
 
 
 
 
4.1
INTRODUCTION
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
4.2.4
CHALLENGES
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNTIES
 
 
 
 
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
 
 
 
5
INDUSTRY TRENDS
Covers the key developments, trend analysis, and actionable insights to support strategic planning and positioning.
 
 
 
 
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
5.2.3
TRENDS IN GLOBAL CANCER DIAGNOSTICS INDUSTRY
 
 
 
5.3
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
5.4
VALUE CHAIN ANALYSIS
 
 
 
 
 
5.5
ECOSYSTEM ANALYSIS
 
 
 
 
 
5.6
PRICING ANALYSIS
 
 
 
 
 
 
5.6.1
AVERAGE SELLING PRICE TREND OF CANCER DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2024-2026
 
 
 
 
5.6.2
AVERAGE SELLING PRICE TREND OF CANCER DIAGNOSTICS PRODUCTS, BY REGION, 2024-2026
 
 
 
5.7
TRADE ANALYSIS
 
 
 
 
 
 
5.7.1
IMPORT SCENARIO
 
 
 
 
5.7.2
EXPORT SCENARIO
 
 
 
5.8
KEY CONFERENCES AND EVENTS, 2026–2027
 
 
 
 
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
5.10
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
5.11
CASE STUDY ANALYSIS
 
 
 
 
5.12
IMPACT OF 2025 US TARIFF – CANCER DIAGNOSTICS MARKET
 
 
 
 
 
 
5.12.1
INTRODUCTION
 
 
 
 
5.12.2
KEY TARIFF RATES
 
 
 
 
5.12.3
PRICE IMPACT ANALYSIS
 
 
 
 
5.12.4
IMPACT ON COUNTRIES/REGIONS
 
 
 
 
 
5.12.4.1
US
 
 
 
 
5.12.4.2
EUROPE
 
 
 
 
5.12.4.3
ASIA PACIFIC
 
 
 
5.12.5
IMPACT ON END USERS
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
 
 
 
 
 
6.1
KEY/EMERGING TECHNOLOGIES
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
6.3
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
6.4
PATENT ANALYSIS
 
 
 
 
 
6.5
FUTURE APPLICATIONS
 
 
 
 
6.6
IMPACT OF AI/GEN AI ON CANCER DIAGNOSTICS MARKET
 
 
 
 
 
 
6.6.1
TOP USE CASES AND MARKET POTENTIAL
 
 
 
 
6.6.2
BEST PRACTICES FOLLOWED BY MANUFACTURERS IN CANCER DIAGNOSTICS MARKET
 
 
 
 
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN CANCER DIAGNOSTICS MARKET
 
 
 
 
6.6.4
INTERCONNECTED/ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
 
 
 
 
6.6.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CANCER DIAGNOSTICS MARKET
 
 
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
 
 
 
 
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
7.2
SUSTAINABILITY INITIATIVES
 
 
 
 
 
7.2.1
ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CANCER DIAGNOSTICS MARKET
 
 
 
 
7.2.2
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
 
 
 
7.3
CERTIFICATIONS, LABELING, ECO-STANDARDS
 
 
 
8
CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
 
 
 
 
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
8.2
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
 
 
 
 
8.3
ADOPTION BARRIERS AND INTERNAL CHALLENGES
 
 
 
 
8.4
UNMET NEEDS OF VARIOUS END USERS
 
 
 
 
8.5
MARKET PROFITIBILITY
 
 
 
9
CANCER DIAGNOSTICS PRODUCT MARKET, BY PRODUCT (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
 
 
 
 
 
9.1
INTRODUCTION
 
 
 
 
9.2
IVD TESTING
 
 
 
 
 
9.2.1
INSTRUMENT
 
 
 
 
 
9.2.1.1
IN SITU HYBRIDIZATION (ISH)
 
 
 
 
9.2.1.2
IMMUNOHISTOCHEMISTRY (IHC)
 
 
 
 
9.2.1.3
NEXT-GENERATION SEQUENCING (NGS)
 
 
 
 
9.2.1.4
MICROARRAY
 
 
 
 
9.2.1.5
FLOW CYTOMETRY
 
 
 
 
9.2.1.6
IMMUNO-ASSAY
 
 
 
 
9.2.1.7
OTHER TECHNOLOGIES
 
 
 
9.2.2
CONSUMABLES
 
 
 
 
 
9.2.2.1
ANTIBODIES
 
 
 
 
9.2.2.2
KITS AND REAGENTS
 
 
 
 
9.2.2.3
PROBES
 
 
 
 
9.2.2.4
OTHER CONSUMABLES
 
 
9.3
ANATOMIC PATHOLOGY
 
 
 
 
 
9.3.1
INSTRUMENT
 
 
 
 
 
9.3.1.1
SLIDE STAINING SYSTEMS
 
 
 
 
9.3.1.2
TISSUE PROCESSING SYSTEMS
 
 
 
 
9.3.1.3
CELL PROCESSORS
 
 
 
 
9.3.1.4
MICROTOMES
 
 
 
 
9.3.1.5
EMBEDDING SYSTEMS
 
 
 
 
9.3.1.6
COVERSLIPPERS
 
 
 
 
9.3.1.7
DIGITAL PATHOLOGY SCANNER
 
 
 
 
9.3.1.8
OTHERS
 
 
 
9.3.2
CONSUMABLES
 
 
 
 
 
9.3.2.1
ANTIBODIES
 
 
 
 
9.3.2.2
KITS AND REAGENTS
 
 
 
 
9.3.2.3
PROBES
 
 
 
 
9.3.2.4
OTHER CONSUMABLES
 
 
9.4
IMAGING BASED
 
 
 
 
 
9.4.1
INSTRUMENT
 
 
 
 
 
9.4.1.1
POSITRON EMISSION TOMOGRAPHY (PET)
 
 
 
 
9.4.1.2
COMPUTED TOMOGRAPHY (CT)
 
 
 
 
9.4.1.3
MAMMOGRAPHY
 
 
 
 
9.4.1.4
ULTRASOUND
 
 
 
 
9.4.1.5
MAGNETIC RESONANCE IMAGING (MRI)
 
 
 
 
9.4.1.6
BIOPSY INSTRUMENTS
 
 
 
 
9.4.1.7
OTHERS
 
 
 
9.4.2
CONSUMABLES
 
 
 
 
 
9.4.2.1
CONTRAST AGENTS
 
 
 
 
9.4.2.2
RADIOPHARMACEUTICALS
 
 
 
 
9.4.2.3
OTHERS
 
10
CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size, Volume & Forecast – USD Million
 
 
 
 
 
10.1
INTRODUCTION
 
 
 
 
10.2
IVD TESTING
 
 
 
 
 
10.2.1
PCR
 
 
 
 
10.2.2
IN SITU HYBRIDIZATION (ISH)
 
 
 
 
10.2.3
IMMUNOHISTOCHEMISTRY (IHC)
 
 
 
 
10.2.4
NEXT-GENERATION SEQUENCING (NGS)
 
 
 
 
10.2.5
MICROARRAY
 
 
 
 
10.2.6
FLOW CYTOMETRY
 
 
 
 
10.2.7
IMMUNO-ASSAY
 
 
 
 
10.2.8
OTHER TECHNOLOGIES
 
 
 
10.3
IMAGING BASED
 
 
 
 
 
10.3.1
MAGNETIC RESONANCE IMAGING (MRI)
 
 
 
 
10.3.2
COMPUTED TOMOGRAPHY (CT)
 
 
 
 
10.3.3
POSITRON EMISSION TOMOGRAPHY (PET)
 
 
 
 
10.3.4
MAMMOGRAPHY
 
 
 
 
10.3.5
ULTRASOUND
 
 
 
10.4
ANATOMIC PATHOLOGY
 
 
 
 
 
10.4.1
HISTOPATHOLOGY
 
 
 
 
10.4.2
CYTOPATHOLOGY
 
 
 
10.5
BIOPSY
 
 
 
11
CANCER DIAGNOSTICS MARKET, BY TYPE
Market Size, Volume & Forecast – USD Million
 
 
 
 
 
11.1
SOLID TUMOR
 
 
 
 
 
11.1.1
LUNG CANCER
 
 
 
 
11.1.2
BREAST CANCER
 
 
 
 
11.1.3
COLORECTAL CANCER
 
 
 
 
11.1.4
GASTRIC CANCER
 
 
 
 
11.1.5
HEAD & NECK CANCER
 
 
 
 
11.1.6
PROSTATE CANCER
 
 
 
 
11.1.7
CERVICAL CANCER
 
 
 
 
11.1.8
MELANOMA
 
 
 
 
11.1.9
OTHERS
 
 
 
11.2
LIQUID TUMOR
 
 
 
 
 
11.2.1
MYELOMA
 
 
 
 
11.2.2
LEUKEMIA
 
 
 
 
11.2.3
LYMPHOMA
 
 
12
CANCER DIAGNOSTICS MARKET, BY APPLICATION
Market Size, Volume & Forecast – USD Million
 
 
 
 
 
12.1
SCREENING AND EARLY DETECTION
 
 
 
 
12.2
DIAGNOSIS AND DISEASE CHARACTERIZATION
 
 
 
 
12.3
TREATMENT DECISION SUPPORT
 
 
 
 
12.4
TREATMENT MONITORING AND DISEASE PROGRESSION ASSESSMENT
 
 
 
 
12.5
POST-TREATMENT SURVEILLANCE AND RECURRENCE DETECTION
 
 
 
13
CANCER DIAGNOSTICS MARKET, BY END USER
Market Size, Volume & Forecast – USD Million
 
 
 
 
 
13.1
INTRODUCTION
 
 
 
 
13.2
HOSPITALS
 
 
 
 
13.3
CLINICAL LABORATORIES
 
 
 
14
CANCER DIAGNOSTICS MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
 
 
 
 
 
14.1
INTRODUCTION
 
 
 
 
14.2
NORTH AMERICA
 
 
 
 
 
14.2.1
US
 
 
 
 
14.2.2
CANADA
 
 
 
14.3
EUROPE
 
 
 
 
 
14.3.1
GERMANY
 
 
 
 
14.3.2
FRANCE
 
 
 
 
14.3.3
UK
 
 
 
 
14.3.4
ITALY
 
 
 
 
14.3.5
SPAIN
 
 
 
 
14.3.6
REST OF EUROPE
 
 
 
14.4
ASIA PACIFIC
 
 
 
 
 
14.4.1
JAPAN
 
 
 
 
14.4.2
CHINA
 
 
 
 
14.4.3
INDIA
 
 
 
 
14.4.4
REST OF ASIA PACIFIC
 
 
 
14.5
LATIN AMERICA
 
 
 
 
14.6
MIDDLE EAST & AFRICA
 
 
 
18
COMPETITIVE LANDSCAPE
 
 
 
 
 
18.1
OVERVIEW
 
 
 
 
18.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
18.3
REVENUE ANALYSIS 2023-2025
 
 
 
 
 
18.4
MARKET SHARE ANALYSIS,
 
 
 
 
 
 
18.4.1
GLOBAL MARKET SHARE ANALYSIS
 
 
 
 
18.4.2
US MARKET SHARE ANALYSIS
 
 
 
18.5
BRAND COMPARISON
 
 
 
 
 
18.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
 
 
 
 
 
 
18.6.1
STARS
 
 
 
 
18.6.2
EMERGING LEADERS
 
 
 
 
18.6.3
PERVASIVE PLAYERS
 
 
 
 
18.6.4
PARTICIPANTS
 
 
 
 
18.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
 
 
 
 
 
18.6.5.1
COMPANY FOOTPRINT
 
 
 
 
18.6.5.2
REGION FOOTPRINT
 
 
 
 
18.6.5.3
PRODUCT FOOTPRINT
 
 
 
 
18.6.5.4
TECHNOLOGY FOOTPRINT
 
 
 
 
18.6.5.5
TYPE FOOTPRINT
 
 
18.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
 
 
 
 
 
 
18.7.1
PROGRESSIVE COMPANIES
 
 
 
 
18.7.2
RESPONSIVE COMPANIES
 
 
 
 
18.7.3
DYNAMIC COMPANIES
 
 
 
 
18.7.4
STARTING BLOCKS
 
 
 
 
18.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
 
 
 
 
 
18.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
18.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
18.8
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
18.9
COMPETITIVE SCENARIO
 
 
 
 
 
18.9.1
PRODUCT LAUNCHES
 
 
 
 
18.9.2
DEALS
 
 
 
 
18.9.3
EXPANSIONS
 
 
19
COMPANY PROFILES
 
 
 
 
 
19.1
KEY PLAYERS
 
 
 
 
 
19.1.1
ROCHE DIAGNOSTICS
 
 
 
 
19.1.2
DANAHER CORPORATION (CEPHEID, LEICA BIOSYSTEMS, BECKMAN COULTER, INTEGRATED DNA TECHNOLOGIES)
 
 
 
 
19.1.3
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
19.1.4
ABBOTT LABORATORIES
 
 
 
 
19.1.5
SIEMENS HEALTHINEERS AG
 
 
 
 
19.1.6
AGILENT TECHNOLOGIES, INC.
 
 
 
 
19.1.7
QIAGEN N.V.
 
 
 
 
19.1.8
ILLUMINA, INC.
 
 
 
 
19.1.9
HOLOGIC, INC.
 
 
 
 
19.1.10
BECTON, DICKINSON AND COMPANY (BD)
 
 
 
 
19.1.11
EXACT SCIENCES CORPORATION
 
 
 
 
19.1.12
GUARDANT HEALTH, INC.
 
 
 
 
19.1.13
FOUNDATION MEDICINE, INC. (A ROCHE COMPANY)
 
 
 
 
19.1.14
SYSMEX CORPORATION
 
 
 
 
19.1.15
BIOMÉRIEUX SA
 
 
 
 
19.1.16
MYRIAD GENETICS, INC.
 
 
 
19.2
OTHER PLAYERS
 
 
 
 
 
19.2.1
NEOGENOMICS LABORATORIES, INC.
 
 
 
 
19.2.2
NATERA, INC.
 
 
 
 
19.2.3
TEMPUS AI, INC.
 
 
 
 
19.2.4
GRAIL, INC.
 
 
 
 
19.2.5
CARIS LIFE SCIENCES
 
 
 
 
19.2.6
PERSONALIS, INC.
 
 
 
 
19.2.7
DELFI DIAGNOSTICS
 
 
 
 
19.2.8
FULGENT GENETICS
 
 
 
 
19.2.9
BURNING ROCK BIOTECH
 
 
 
 
19.2.10
GENETRON HEALTH
 
 
20
RESEARCH METHODOLOGY
 
 
 
 
 
20.1
RESEARCH DATA
 
 
 
 
 
20.1.1
SECONDARY DATA
 
 
 
 
 
20.1.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
20.1.1.2
LIST OF KEY SECONDARY SOURCES
 
 
 
20.1.2
PRIMARY DATA
 
 
 
 
 
20.1.2.1
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
20.1.2.2
KEY PRIMARY PARTICIPANTS
 
 
 
 
20.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
20.1.2.4
KEY INDUSTRY INSIGHTS
 
 
20.2
MARKET SIZE ESTIMATION
 
 
 
 
 
20.2.1
BOTTOM-UP APPROACH
 
 
 
 
20.2.2
TOP-DOWN APPROACH
 
 
 
 
20.2.3
MARKET SIZE CALCULATION FOR BASE YEAR
 
 
 
20.3
MARKET FORECAST APPROACH
 
 
 
 
 
20.3.1
SUPPLY SIDE
 
 
 
 
20.3.2
DEMAND SIDE
 
 
 
20.4
DATA TRIANGULATION
 
 
 
 
20.5
FACTOR ANALYSIS
 
 
 
 
20.6
RESEARCH ASSUMPTIONS
 
 
 
 
20.7
RESEARCH LIMITATIONS
 
 
 
 
20.8
RISK ASSESSMENT
 
 
 
21
APPENDIX
 
 
 
 
 
21.1
DISCUSSION GUIDE
 
 
 
 
21.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
21.3
CUSTOMIZATION OPTIONS
 
 
 
 
21.4
RELATED REPORTS
 
 
 
 
21.5
AUTHOR DETAILS
 
 
 

 

Methodology

The study involved major activities in estimating the current market size for the Cancer Diagnostics  market. Exhaustive secondary research was done to collect information on the Cancer Diagnostics  market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the Cancer Diagnostics  market.

Secondary Research

This research study involved the wide use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, Factiva, whitepapers, and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the Cancer Diagnostics  market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply- and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, VPs/Managing Directors, Marketing Heads/Directors and Sales Directors, Marketing/Sales Managers, Regional/Area Sales Managers, Export/Import Heads/Managers, and Other Cancer Diagnostics  Market Related Personnel from various companies and organizations operating in the Cancer Diagnostics  market. Primary sources from the demand side included Law Enforcement Agencies Vice Presidents,C-level Executives, Department Heads, Enterprises, Individuals, Supply Management Team of Hospitals, Clinic Personnel, and Laboratory Technicians.

Breakdown of Primary Interviews

Cancer Diagnostics Market Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primaries include sales, marketing, and product managers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the Cancer Diagnostics  market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Cancer Diagnostics Market : Top-Down and Bottom-Up Approach

Cancer Diagnostics Market Top Down and Bottom Up Approach

Data Triangulation

The entire market was split into two segments when the market size was determined. Data triangulation and market breakdown processes were used where necessary to complete the entire market engineering process and arrive at precise statistics for all segments.

Approach to derive the market size and estimate market growth.

Using secondary data from paid and unpaid sources, the market rankings for the major players were determined following a thorough analysis of their sales of Cancer Diagnostics . Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.

Market Definition

Cancer diagnostics refers to the tests, technologies, and procedures used to detect, diagnose, characterize, and monitor cancer, enabling early detection, accurate diagnosis, treatment selection, and disease monitoring. The market includes imaging, molecular diagnostics, biopsy-based testing, immunohistochemistry (IHC), next-generation sequencing (NGS), liquid biopsy, and companion diagnostics, serving hospitals, diagnostic laboratories, cancer centers, and research institutes.

Key Stakeholders

  • Diagnostic test and kit manufacturers
  • Medical device and imaging equipment manufacturers
  • Molecular diagnostics and genomics companies
  • Hospitals and healthcare systems
  • Diagnostic laboratories (clinical and reference laboratories)
  • Cancer centers and oncology clinics
  • Physicians (oncologists, pathologists, radiologists, and primary care physicians)
  • Academic and research institutes
  • Pharmaceutical and biotechnology companies (companion diagnostics and precision medicine)
  • Contract research organizations (CROs)
  • Government and public health agencies
  • Regulatory authorities
  • Health insurance providers and payers
  • Patients and patient advocacy organizations
  • Distributors and healthcare suppliers

Report Objectives

  • To describe, analyze, and forecast the Cancer Diagnostics  market, by product, type, application, technology, end user, and region.
  • To describe and forecast the Cancer Diagnostics  market for key regions, namely, North America, Europe, the Asia Pacific, Latin America and Middle East and Africa
  • To provide detailed information regarding drivers, restraints, opportunities, and challenges influencing the growth of the Cancer Diagnostics  market
  • To strategically analyze the ecosystem, regulations, patenting trend, value chain, Porter’s five forces, and prices pertaining to the market under study
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
  • To profile key players and comprehensively analyze their market shares and core competencies2 in the Cancer Diagnostics  market
  • To analyze competitive developments such as collaborations, acquisitions, product launches, expansions, and R&D activities in the Cancer Diagnostics  market

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of each company

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific Cancer Diagnostics  market into Vietnam, New Zealand, and others.
  • Further breakdown of the Rest of Latin America Cancer Diagnostics  market into Columbia, Chile, Ecuador, and others.
  • Further breakdown of the Rest of Europe Cancer Diagnostics  market into Belgium, Russia, Netherlands, Switzerland, and others.
 

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Cancer Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Cancer Diagnostics Market

avtar

Christian

May, 2022

Need accurate market data of Cancer Diagnostics Market Size, share and Forecasts upto 2030.

avtar

Abigail

Mar, 2022

What are the growth expectations for the leading players in the global Cancer Diagnostics Market?.

avtar

Jean

Mar, 2022

Which factors are proving to be the growth boosters for the North American region of the Cancer Diagnostics Market?.

DMCA.com Protection Status
popup img